Three months after Olivier Brandicourt took over as CEO of Sanofi he announced plans to restructure the French drugmaker into five global business units.

The business units are: general medicines and emerging markets; specialty care, which will be called Sanofi Genzyme; diabetes and cardiovascular; Sanofi Pasteur, its vaccine business; and Merial, the portfolio of animal-health products.

The reorganization, which is expected to go into effect in January, “simplifies and focuses Sanofi to optimize growth,” Brandicourt said in a news release. The restructuring was announced Wednesday.